Principal Investigator William A. Greisner III, M.D., has extensive research experience dating back to 1998. Below you will find a detailed record of the industry-sponsored clinical research studies he has participated in and his role in the studies. The entire research resume is available as a pdf document which can be downloaded using the link below.
Site Principal Investigator. Schering-Plough Corporation. Phase IV Study. P97-293-0469. A Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Treatment of Seasonal Allergic Rhinitis (SAR) in Subjects with Co-Morbid Asthma and a History of Seasonal Exacerbations of Asthma on Medical Resources Utilization (for Asthma and SAR). 1998-1999.
Site Principal Investigator. Schering-Plough Corporation. Phase IV Study. P00187-15. A Double-Blind, Double Dummy Clinical Trail to Evaluate the Efficacy and Safety of Mometasone Furoate Dry Powder Inhaler (DPI) 220 mcg QD Given Once Daily in the Evening and Singulair (Montelukast Sodium) Tablets in Steroid Naive Subjects With Asthma. 2000.
Site Sub-investigator. Health Benchmarks, Inc. Post-marketing Study. RES41176. REACH (A Prospective, Nonrandomized Registry Comparing the Clinical, Humanistic, and Economic Outcomes of Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50 mcg with Montelukast 10 mg in Patients Previously Controller-Naive or Prescribed an Inhaled Corticosteroid). 2002.
Site Principal Investigator. Novartis Pharmaceuticals Corporation and Genentech, Inc. Post-marketing Study. CHARIOT (Characterization of Allergic Asthma: A Chart Review In Moderate-to-Severe Disease to Assess Asthma Control, Patient Outcomes and Treatment Study). 2006-2007.
Site Principal Investigator. Novartis. Post-marketing Study. HEORUSV200328. Understanding Refractory Chronic Idiopathic Urticaria (CIU) in the US. 2015.
Site Principal Investigator. Allergy Therapeutics (UK) Ltd. Phase II Study. GrassMATAMPL204. A double-blind randomized parallel group study of three cumulative doses of Grass MATA MPL compared to placebo and Grass MATA in patients with seasonal allergic rhinoconjuncitivitis exposed to grass pollen in Mobile Environmental Exposure Chambers (mEECs) out of the grass pollen season. 2015-2017.
Site Principal Investigator. General Innovations and Goods, Inc./National Institutes of Health (NIH). Pivotal Study. U44-CRE-01. A Double Blind, Randomized, Sham Controlled Trial to Investigate the Effect of the CREON2000A on Asthma Control in Children with Mild to Moderate Persistent Asthma. 2016-2019.
Site Principal Investigator. Stallergenes. Phase III Study. SL75.14. A randomized, double-blind, placebo-controlled, multi-center study of the efficacy and safety of STG320 sublingual tablets of house dust mite (HDM) allergen extracts in adults and adolescents with HDM-associated allergic rhinitis. 2017-2018.
Site Principal Investigator. AstraZeneca. Post-marketing Study. EVA-21277-00. Understanding Patient and Medical Professional Perceptions of, and Preferences for, Biologic Therapy in Severe, Uncontrolled Asthma. 2017-2018.
Site Principal Investigator. AstraZeneca. Observational Study. D3250R00023. The CHRONICLE Study: A Longitudinal Prospective Observational Study of the Characteristics, Treatment Patterns and Health Outcomes of Individuals with Severe Asthma in the United States. 2018-
Site Principal Investigator. AstraZeneca. Observational Study. EVA-23313-00. Cognitive Patient Interviews to Assess an Asthma Risk Screener. 2018.
Site Principal Investigator. AstraZeneca. Observational Study. EVA-24053. A Cross-Sectional and Longitudinal Observational Primary Data Collection Study to Assess the Validity of the US Asthma Impairment and Risk Questionnaire (AIRQ) as a Tool that Identifies Patients with Asthma at Risk for Adverse Outcomes from Uncontrolled Asthma. 2019-2020.
Site Principal Investigator. ALK. Phase III Study. MT-12. A one-year placebo-controlled phase III trial evaluating the efficacy and safety of the house dust mite (HDM) SLIT-tablet in children (5-11 years of age) with HDM allergic rhinitis/rhinoconjunctivitis with or without asthma. 2019-2022.
Site Principal Investigator. Allergy Therapeutics (UK) Ltd. Phase II/III Study. PQGrass309. A randomised, double-blind, placebo-controlled exploratory study to explore the efficacy and safety of PQ Grass 27600 SU in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass pollen exposure. 2020-2022.
Site Principal Investigator. Pfizer. Expanded Access Study. PF-04965842. Abrocitinib Expanded Access Protocol in Adolescents and Adults with Moderate to Severe Atopic Dermatitis. 2021-2022.
Site Principal Investigator. Teva Branded Pharmaceutical Products R&D, Inc. Phase IV Study. FSS-AS-40139. CONNected Electronic Inhalers Asthma Control Trial 2 (“CONNECT 2”), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older with Asthma. 2021-2022.
Site Principal Investigator. GlaxoSmithKline LLC. Phase IIIa Study. Nimble-206785. A 52-week, randomised, double-blind, double-dummy, parallel group, multi-centre, non-inferiority study assessing exacerbation rate, additional measures of asthma control and safety in adult and adolescent severe asthmatic participants with an eosinophilic phenotype treated with GSK3511294 compared with mepolizumab or benralizumab (Nimble). 2021-
Site Principal Investigator. Regeneron Pharmaceuticals, Inc. Phase III Study. R1908-1909-ALG-2102. A Randomized, Double-Blind, Placebo-Controlled Study in Cat-Allergic Patients with Allergic Rhinitis Who Live with a Cat to Assess the Efficacy and Safety of Anti-Fel d 1 Antibodies during Natural Cat Exposure in the Home. 2021-2023.
Site Principal Investigator. GlaxoSmithKline LLC. Phase IIIa. Swift 1-206713 A 52-week, randomised, double-blind, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of GSK3511294 adjunctive therapy in adult and adolescent participants with severe uncontrolled asthma with an eosinophilic phenotype (Swift 1). 2021-2023.
Site Principal Investigator. Novartis Pharmaceuticals Corporation. CLOU064A2301 Phase III. A multicenter, randomized, double-blind, placebo-controlled Phase 3 study of remibrutinib (LOU064) to investigate the efficacy, safety and tolerability for 52 weeks in adult chronic spontaneous urticaria (CSU) patients inadequately controlled by H1-antihistamines (REMIX-1). 2021-2023.
Site Principal Investigator. AstraZeneca LP. D5982C00006. Pivotal Phase III Study. A Randomized, Double-Blind, Active Controlled, Parallel Group, Multicenter 24 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered-Dose Inhaler Relative to Budesonide Metered Dose Inhaler and Open-Label Symbicort Turbuhaler in Participants with Inadequately Controlled Asthma (VATHOS). 2021-
Site Principal Investigator. Amgen Inc. 20190194. A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging, Phase 2b Study to Evaluate Efficacy and Safety of Tezepelumab for the Treatment of Chronic Spontaneous Urticaria (INCEPTION). 2022-2023.
Site Principal Investigator. AstraZeneca AB. Phase IIa Study. D7552C00001. A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of Atuliflapon Given Orally Once Daily for Twelve Weeks in Adults with Moderate to Severe Uncontrolled Asthma (FLASH). 2022-
Site Principal Investigator. Allergy Therapeutics (UK) Ltd. Phase III Study. PQGrass306. A randomised, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of PQ Grass in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass pollen exposure. 2022-2023.
Site Principal Investigator. AstraZeneca AB. Phase IV Study. D5180C00032. A Multicenter, Single-arm, Open-label, Post-Authorization, Phase 4 Effectiveness and Safety Study of Tezepelumab in Adult and Adolescent Participants with Severe Asthma including Several Under-Studied Populations in the United States (PASSAGE). 2022-
Site Principal Investigator. Allakos Inc. Phase II Study. AK002-027. A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lirentelimab in Adult Subjects with H-1 Antihistamine Refractory Chronic Spontaneous Urticaria. 2022-2024.
Site Principal Investigator. Allakos Inc. Phase II Study. AK002-018. A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Lirentelimab in Adult Subjects with Moderate-to-Severe Atopic Dermatitis Inadequately Controlled by Topical Treatments (ATLAS). 2022-2024.
Site Principal Investigator. GlaxoSmithKline LLC. Phase 3a Study. 212895. A multi-centre, single arm, open-label extension study to evaluate the long-term safety of GSK3511294 (Depemokimab) in adult and adolescent participants with severe asthma with an eosinophilic phenotype from studies 206713 or 213744 (AGILE). 2022-
Site Principal Investigator. Amgen Inc. Phase 3 Study. 20210263. A Phase 3, Open-label, 52-week Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab (AMG 451) in Adolescent Subjects Aged >/= 12 to < 18 years With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Orbit. 2023-2024.
Site Principal Investigator. AstraZeneca Pharmaceuticals LP. Phase III Study. D5982C00005. A Randomized, Double-Blind, Parallel Group, Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma (LITHOS). 2023-
Site Principal Investigator. Novartis Pharmaceuticals Corporation. Phase II Study. CLOU064/12201. A one month, investigator and participant blinded study to investigate the efficacy and safety of remibrutinib (LOU064) at multiple dose levels in adult participants with peanut allergy. 2023-2024.
Site Principal Investigator. Teva Branded Pharmaceutical Products R&D, Inc. Phase 3. FpA-AS-30094. A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients with Asthma (FLAIR). 2023-
Site Principal Investigator. Allakos Inc. Phase 1. AK006-001. A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Sequential, Single- and Multiple- Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of AK006 in Healthy Subjects and in Subjects with H1 Antihistamine Refractory Chronic Spontaneous Urticaria. 2024-
Site Principal Investigator. GlaxoSmithKline Research & Development Limited. Phase 4. 219871. A prospective, real-world, interventional study to evaluate the effect of mepolizumab on achieving clinical remission in participants with severe asthma (REIMAGINE). 2024-
Site Principal Investigator. Eli Lilly and Company. Phase 3. J2T-MC-KGBT. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lebrikizumab/LY3650150 in Adult Participants with Perennial Allergic Rhinitis. 2024-
Site Principal Investigator. Regeneron Pharmaceuticals, Inc. Phase IV. R668-AS-2373. AIM4: Next Step – Asthma Uncontrolled With ICS in Medium Dose (GINA 4): Next Step; Efficacy of Dupilumab Added to Medium Dose ICS/LABA in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Patients With Uncontrolled Asthma (AIM 4 Next Step). 2024-
Site Principal Investigator. Allakos Inc. Phase 1. AK006-001X. An Open-Label Extension Study Evaluating the Safety, Tolerability, PK, Immunogenicity, and Clinical Response of Multiple Doses of IV AK006 in Subjects With H1 Antihistamine Refractory Chronic Spontaneous Urticaria Completing Study AK006-001. 2024-
Site Principal Investigator. Nocion Therapeutics, Inc. Phase 2b. NOC110-C-202. A Phase 2b, Randomized, Double-Blind, Placebo -Controlled Study to Assess the Efficacy, Safety, and Tolerability of Taplucainium Inhalation Powder (NOC-110) in Adults with Refractory or Unexplained Chronic Cough (ASPIRE). 2024-
© Copyright Bluegrass Allergy Research